News
NRXS
7.41
+2.21%
0.16
Weekly Report: what happened at NRXS last week (0330-0403)?
Weekly Report · 22h ago
Top NeurAxis Insiders Make Bold Moves With Fresh Stock Buys
TipRanks · 3d ago
Weekly Report: what happened at NRXS last week (0323-0327)?
Weekly Report · 03/30 10:15
NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth
NASDAQ · 03/24 15:09
Weekly Report: what happened at NRXS last week (0316-0320)?
Weekly Report · 03/23 10:12
Neuraxis Is Maintained at Buy by Craig-Hallum
Dow Jones · 03/20 17:27
Craig-Hallum Maintains Buy on Neuraxis, Raises Price Target to $13
Benzinga · 03/20 17:17
Neuraxis price target raised to $13 from $8 at Craig-Hallum
TipRanks · 03/20 12:56
NeurAxis Earnings Call: Reimbursement Wins Drive Next Phase
TipRanks · 03/20 00:10
NeurAxis reports Q4 results
Seeking Alpha · 03/19 11:15
Earnings Scheduled For March 19, 2026
Benzinga · 03/19 11:11
Press Release: NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
Dow Jones · 03/19 11:05
Press Release: NeurAxis Reports Strong Fourth -2-
Dow Jones · 03/19 11:05
Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC)
TipRanks · 03/17 13:50
Weekly Report: what happened at NRXS last week (0309-0313)?
Weekly Report · 03/16 10:11
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 03/13 21:05
Weekly Report: what happened at NRXS last week (0302-0306)?
Weekly Report · 03/09 10:11
Weekly Report: what happened at NRXS last week (0223-0227)?
Weekly Report · 03/02 10:11
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 02/23 17:05
Weekly Report: what happened at NRXS last week (0216-0220)?
Weekly Report · 02/23 10:11
More
Webull provides a variety of real-time NRXS stock news. You can receive the latest news about Neuraxis Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXS
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.